Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : BML-281
CAS No.: 1045792-66-2
Catalog No.: PC-60692Not For Human Use, Lab Use Only.
BML-281 (CAY10603) is a potent, selective HDAC6 inhibitor with IC50 of 0.002 nM, weakly inhibits HDAC3 (IC50=0.42 nM) and >50,000-fold selectivity over HDAC1/2/8/10.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $118 | In stock | |
| 10 mg | $178 | In stock | |
| 25 mg | $318 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
BML-281 (CAY10603) is a potent, selective HDAC6 inhibitor with IC50 of 0.002 nM, weakly inhibits HDAC3 (IC50=0.42 nM) and >50,000-fold selectivity over HDAC1/2/8/10.
BML-281 (CAY10603) blocks pancreatic cancer cell growth with IC50 of <1 uM.
BML-281 (CAY10603) selectively reduces lamina propria B-cell infiltrate and suppresses CD19+ B lymphocyte influx into DSS-inflamed lamina propria, elicits broad-spectrum anti-inflammatory effects in DSS-induced colitis in mice.
| M.Wt | 446.5 | |
| Formula | C22H30N4O6 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
N-Hydroxy-7-[5-(4-tertbutoxycarbonylaminophenyl)-3-isoxazolecarboxamido]heptanamide |
|
1. Lohman RJ, et al. J Pharmacol Exp Ther. 2016 Feb;356(2):387-96.
2. Do A, et al. J Pharmacol Exp Ther. 2017 Jan;360(1):140-151.
3. Kozikowski AP, et al. J Med Chem. 2008 Aug 14;51(15):4370-3.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
